Patient-specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity
β‘οΈ buff.ly/OpVpLqS
#Pharmacogenomics
@moloncology.bsky.social
Open access journal highlighting new discoveries, technical developments and policies in basic, translational, and clinical cancer research. Part of FEBS Press. moloncol.org
Patient-specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity
β‘οΈ buff.ly/OpVpLqS
#Pharmacogenomics
π Did you know we publish EACR Viewpoints?
π£ Introduced in 2023 when Molecular Oncology became the affiliate journal of the
EACR, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch.
π You may access them here
β‘οΈ bit.ly/4cIqPCh
@FEBSnews #CancerBiology
π£ New month, new Commentary
Not just a by-product: circular DNA molecules derived from V(D)J recombination are linked to worse prognosis in B-cell leukemia
π buff.ly/hO4fJ9g
ποΈ @andreaventura.bsky.social
#eccDNA #ecDNA
The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis
β‘οΈ buff.ly/XfueJAy
#CTCs #mCRC #Prognosis #Oncology #CRCSM
π Have you leafed through our September Issue?
This Issue contains recent findings on how TME changes can alter cell function and treatment outcomes. It also highlights new therapeutic opportunities based on the TMEβs dynamic landscape
π buff.ly/jYUuWIM
#TumourMicroenvironment
Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia
β‘οΈ buff.ly/yxF616I
ποΈ @HeckmanLab
#AML #MCL1 #HemOnc
π€© We are excited to be attending π§ EACR Cancer Neuroscienceπ§ next month
π₯ Are you going?
π buff.ly/lTaWPhW
#CancerResearch #BrainTumours
#CNScancer #NeuroOncology
π£The joint publishing fellowship with the EACR @helloeacr offers a remote placement at the journal
Get hands-on experience in scientific editing and visit the Heidelberg office
β°Deadline Nov 7
β‘οΈhttps://buff.ly/3ZtvMe3
#PhDchat #PostDocChat #ECRchat
#CancerResearch #CancerBiology
Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism
π¦ buff.ly/SkrGsPb
#Glioma #Metabolism
π£ Don't miss our new Commentary
Only the strong survive: therapeutic selective pressure drives medulloblastoma leptomeningeal metastasis
ποΈ @MSKCancerCenter @adrienne_boire
#Leptomeningeal #Metastasis #Medulloblastoma
π’Call for papers
πSubmit your latest research in the field of #LiquidBiopsy
β‘οΈFormat: Research Article, Short Report or Method
β‘οΈDetails buff.ly/ATND9t1
#ACTC2025 #CTC #ctDNA #Cancer
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy
β‘οΈ buff.ly/8wmhhmv
ποΈ @GroupKyte
#Microbiome #GutMicrobiota #BCSM #Immunotherapy
π»If you believe that curated data = quality controlled data then check out
@datadryad
π€Thanks to our partnership, authors can now enable the open sharing & reuse of their research data
πhttps://buff.ly/3BkrNqd
#OpenSource #OpenAccess #OpenResearch #OpenData #OpenScience
π Did you know we publish EACR Viewpoints?
π£ Introduced in 2023 when Molecular Oncology became the affiliate journal of the
@EACRnews, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch
π You may access them here
β‘οΈ bit.ly/4cIqPCh
@FEBSnews #CancerBiology
Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics
π¦ buff.ly/dsaLPGJ
#Fragmentomics #ctDNA #DNAmet #DNAmethylation
The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients
π buff.ly/X1aoIai
#ROS1 #NSCLC #Oncofusions
β οΈDid you know?
π£Molecular Oncology is an affiliate journal with Review Commons, meaning #ReviewedPreprints can be transferred directly to the journal for editorial consideration without restarting #PeerReview
β Did you book your spot yet?
π§ EACR Cancer Neuroscienceπ§
πRegister by Sept 15
buff.ly/lTaWPhW
#CancerResearch #BrainTumours
#CNScancer #NeuroOncology
π We are looking for papers!
π€ In conjunction with the @EACRnews conference on #ImmunoOncology we have an active call for papers!
π© Submit your latest research in the field of #CancerImmunology #ImmunoOnc
π Find out more details buff.ly/ZDb3rO0
Adenosine-to-inosine editing of miR-200b-3p is associated with the progression of high-grade serous ovarian cancer
π buff.ly/FMrZvtO
#HGSOC #miR200 #RNAediting
Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer
π¦ buff.ly/1ZZBtJh
ποΈ @DrLitvinov
#Merkelcellcarcinoma
Bridging the gap: Multi-stakeholder perspectives of molecular diagnostics in oncology
π buff.ly/ERfd897
ποΈ @TimonV
#MolOncology #Oncology #MolecularDiagnostics
YAP1::TFE3 mediates endothelial-to-mesenchymal plasticity in epithelioid hemangioendothelioma
π buff.ly/r55RHc7
π£ There is still time to surf through our August Issue
π‘ Find a new EACR Viewpoint on integrating temporal dynamics into cancer research by Guillaume Jacquemet @guijacquemet.bsky.social
πββοΈ buff.ly/pUt8m16
π£ Have you seen our latest Commentary?
SensRORing cholesterol to drive protumoral myelopoiesis
π buff.ly/tzuHla3
#Metabolism #Cholesterol #Myelopoiesis
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
π buff.ly/4OGCRch
#HGSOC #Chemoresistance
Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer
β‘οΈ buff.ly/vPDXjxq
#TNBC #PARPi
π We are looking for papers!
π€ In conjunction with the recent @EACRnews conference on #ImmunoOncology we have an active call for papers!
π© Submit your latest research in the field of #CancerImmunology #ImmunoOnc
ποΈ Research Article, Short Report or Method
π Find out more details buff.ly/ZDb3rO0
β³ There is still time to register and attend!
βοΈEACR Goodbye Flat Biology: ex vivo to in vivo models of cancerβοΈ
πRegister by Aug 26
π‘ buff.ly/3XkCk1h
#CancerModels #CancerModel #PreclinicalResearch #ModelOrganisms #TumourModels
Multi-omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine
β‘οΈ buff.ly/yKCCKjU
#CRCSM #PrecisionMedicine